16:33 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Berlin Cures' heart failure candidate well tolerated in Phase I

Berlin Cures Holding AG (Zug, Switzerland) reported data from a Phase I trial in 68 healthy volunteers showing that a single IV infusion of heart failure candidate BC007 was well tolerated and eliminated autoantibodies against...
14:35 , Nov 17, 2016 |  BC Week In Review  |  Clinical News

BC007: Ph I started

Berlin Cures began a dose-escalation, German Phase I trial of BC007 given as an IV bolus plus infusion in about 44 healthy volunteers. A double-blind, placebo-controlled part will evaluate single doses of 15, 50 and...